Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but filing text confirms "Synthetic Blood International, Inc.")
Reporting Period: Quarterly period ended October 31, 2002 (Six months ended October 31, 2002 for comparative data).
Status: Development Stage Company. The firm is in the pre-clinical trial stage for its blood substitute product, "Oxycyte," and has no commercial revenue. Operations are funded through debt and equity financing.
Key Financial Metrics
| Metric | Six Months Ended Oct 31, 2002 | Six Months Ended Oct 31, 2001 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,427,370) | $(1,039,148) |
| Accumulated Deficit | $(17,900,763) | $(16,473,393) |
| Cash and Cash Equivalents (End of Period) | $1,035,062 | $3,496,526 |
| Working Capital | $944,721 | Not explicitly stated |
| Cash Used in Operating Activities | $(1,272,019) | $(897,452) |
| Current Liabilities | $113,431 | $179,078 |
Expense Breakdown (Six Months 2002):
- Research and Development: $1,013,547
- General and Administrative: $443,015
- Interest Expense: $3,150
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $388,222 (37%) compared to the prior six-month period. This was driven by a $333,237 increase in operating expenses and a $54,985 decrease in other income (interest income).
- R&D Spike: Research and Development expenses rose 52% to $1,013,547, attributed to a significant increase in animal research studies for the Oxycyte product. Contract consulting and salary expenses increased by $311,500.
- Cash Position: Cash and cash equivalents declined from $2,442,015 at the start of the period to $1,035,062 at period end, a reduction of approximately $1.4 million.
- Financing Activity: The company raised $13.9 million in proceeds from the sale of common stock and exercise of options/warrants during the six-month period, offsetting operating cash burn.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern. Continuation depends on obtaining additional financing for further development and testing.
- Liquidity: Management believes current cash ($1.035 million) is sufficient to meet projected needs for the next 6 months. There are no firm commitments for additional capital as of October 31, 2002.
- Regulatory Risks: Products are in the pre-clinical stage. Risks include failure to achieve results in pre-clinical studies, inability to obtain FDA approval for clinical trials, and potential patent infringement issues.
- Capital Requirements: Future funding is critical. If strategic partners do not assume Phase III costs, financing requirements will increase substantially. Failure to raise funds may force the company to delay programs or sell technology rights.
Investor Verification Checklist
- Runway Validation: Verify if the $1.035 million cash balance is sufficient to cover the projected 6-month burn rate given the accelerating R&D spend.
- Financing Pipeline: Confirm the status of any private or institutional financing discussions mentioned as "actively pursued."
- R&D Milestones: Assess the specific outcomes of the "significant increase in animal research studies" to determine if FDA submission for clinical trials is imminent.
- Dilution Risk: Review the impact of recent equity issuances (36,629 shares exercised recently; 300,000 options granted) on existing shareholder ownership.
- Contractual Obligations: Verify the $113,000 in outstanding research contracts due through January 2003.